Studies related to Liver Cirrhosis and Vitamin E

Pioglitazone, Vitamin E, Or Placebo For Nonalcoholic Steatohepatitis

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 222
Sex Both Genders
Age Range 30-44, 45-64
Body Types Obese
Notes for this study:
Supplementation of 800 IU vitamin E (as alpha-tocopherol) daily for 96 weeks in persons with non-alcoholic fatty liver disease (NAFLD) appeared to reduce circulating ALT and liver fat scores in approximately 50% of the group (more than placebo) although liver fibrosis was not affected.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.